ID   SPTC1_HUMAN             Reviewed;         473 AA.
AC   O15269; A8K681; Q5VWB4; Q96IX6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Serine palmitoyltransferase 1;
DE            EC=2.3.1.50;
DE   AltName: Full=Long chain base biosynthesis protein 1;
DE            Short=LCB 1;
DE   AltName: Full=Serine-palmitoyl-CoA transferase 1;
DE            Short=SPT 1;
DE            Short=SPT1;
GN   Name=SPTLC1; Synonyms=LCB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=9363775; DOI=10.1111/j.1432-1033.1997.00239.x;
RA   Weiss B., Stoffel W.;
RT   "Human and murine serine-palmitoyl-CoA transferase. Cloning,
RT   expression and characterization of the key enzyme in sphingolipid
RT   synthesis.";
RL   Eur. J. Biochem. 249:239-247(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANTS
RP   HSAN1A TRP-133; TYR-133 AND ASP-144.
RX   PubMed=11242114; DOI=10.1038/85879;
RA   Dawkins J.L., Hulme D.J., Brahmbhatt S.B., Auer-Grumbach M.,
RA   Nicholson G.A.;
RT   "Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain
RT   base subunit-1, cause hereditary sensory neuropathy type I.";
RL   Nat. Genet. 27:309-312(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=17023427; DOI=10.1074/jbc.M608066200;
RA   Hornemann T., Richard S., Ruetti M.F., Wei Y., von Eckardstein A.;
RT   "Cloning and initial characterization of a new subunit for mammalian
RT   serine-palmitoyltransferase.";
RL   J. Biol. Chem. 281:37275-37281(2006).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE SPT COMPLEX, AND
RP   INTERACTION WITH SPTSSA AND SPTSSB.
RX   PubMed=19416851; DOI=10.1073/pnas.0811269106;
RA   Han G., Gupta S.D., Gable K., Niranjanakumari S., Moitra P.,
RA   Eichler F., Brown R.H. Jr., Harmon J.M., Dunn T.M.;
RT   "Identification of small subunits of mammalian serine
RT   palmitoyltransferase that confer distinct acyl-CoA substrate
RT   specificities.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8186-8191(2009).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANT HSAN1A
RP   TRP-133.
RX   PubMed=20504773; DOI=10.1074/jbc.M110.122259;
RA   Gable K., Gupta S.D., Han G., Niranjanakumari S., Harmon J.M.,
RA   Dunn T.M.;
RT   "A disease-causing mutation in the active site of serine
RT   palmitoyltransferase causes catalytic promiscuity.";
RL   J. Biol. Chem. 285:22846-22852(2010).
RN   [10]
RP   INTERACTION WITH ORMDL3.
RX   PubMed=20182505; DOI=10.1038/nature08787;
RA   Breslow D.K., Collins S.R., Bodenmiller B., Aebersold R., Simons K.,
RA   Shevchenko A., Ejsing C.S., Weissman J.S.;
RT   "Orm family proteins mediate sphingolipid homeostasis.";
RL   Nature 463:1048-1053(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION AT TYR-164, AND MUTAGENESIS OF TYR-164.
RX   PubMed=23629659; DOI=10.1074/jbc.M112.409185;
RA   Taouji S., Higa A., Delom F., Palcy S., Mahon F.X., Pasquet J.M.,
RA   Bosse R., Segui B., Chevet E.;
RT   "Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1)
RT   on tyrosine 164 inhibits its activity and promotes cell survival.";
RL   J. Biol. Chem. 288:17190-17201(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   VARIANT ALA-387.
RX   PubMed=15037712; DOI=10.1212/01.WNL.0000115388.10828.5C;
RA   Verhoeven K., Coen K., De Vriendt E., Jacobs A., Van Gerwen V.,
RA   Smouts I., Pou-Serradell A., Martin J.-J., Timmerman V., De Jonghe P.;
RT   "SPTLC1 mutation in twin sisters with hereditary sensory neuropathy
RT   type I.";
RL   Neurology 62:1001-1002(2004).
RN   [15]
RP   VARIANT LEU-151.
RX   PubMed=17060578; DOI=10.1212/01.wnl.0000240068.21499.f5;
RA   Meggouh F., Bienfait H.M.E., Weterman M.A.J., de Visser M., Baas F.;
RT   "Charcot-Marie-Tooth disease due to a de novo mutation of the RAB7
RT   gene.";
RL   Neurology 67:1476-1478(2006).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-239.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [17]
RP   VARIANTS HSAN1A PHE-331 AND VAL-352.
RX   PubMed=19651702; DOI=10.1093/brain/awp198;
RA   Rotthier A., Baets J., De Vriendt E., Jacobs A., Auer-Grumbach M.,
RA   Levy N., Bonello-Palot N., Kilic S.S., Weis J., Nascimento A.,
RA   Swinkels M., Kruyt M.C., Jordanova A., De Jonghe P., Timmerman V.;
RT   "Genes for hereditary sensory and autonomic neuropathies: a genotype-
RT   phenotype correlation.";
RL   Brain 132:2699-2711(2009).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS HSAN1A TYR-133; TRP-133 AND ASP-144,
RP   CHARACTERIZATION OF VARIANT ALA-387, AND LACK OF ASSOCIATION OF
RP   VARIANT ALA-387 WITH HSAN1A.
RX   PubMed=19132419; DOI=10.1007/s10048-008-0168-7;
RA   Hornemann T., Penno A., Richard S., Nicholson G., van Dijk F.S.,
RA   Rotthier A., Timmerman V., von Eckardstein A.;
RT   "A systematic comparison of all mutations in hereditary sensory
RT   neuropathy type I (HSAN I) reveals that the G387A mutation is not
RT   disease associated.";
RL   Neurogenetics 10:135-143(2009).
RN   [19]
RP   VARIANT HSAN1A PHE-331, AND CHARACTERIZATION OF VARIANTS HSAN1A
RP   PHE-331 AND VAL-352.
RX   PubMed=21618344; DOI=10.1002/humu.21481;
RA   Rotthier A., Penno A., Rautenstrauss B., Auer-Grumbach M.,
RA   Stettner G.M., Asselbergh B., Van Hoof K., Sticht H., Levy N.,
RA   Timmerman V., Hornemann T., Janssens K.;
RT   "Characterization of two mutations in the SPTLC1 subunit of serine
RT   palmitoyltransferase associated with hereditary sensory and autonomic
RT   neuropathy type I.";
RL   Hum. Mutat. 32:E2211-E2225(2011).
RN   [20]
RP   VARIANT HSAN1A TRP-133, AND VARIANT GLY-310.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A.,
RA   Muntoni F., Blake J., Brandner S., Davies N., Horvath R., Price S.,
RA   Donaghy M., Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P.,
RA   Manji H., Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary
RT   sensory and autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [21]
RP   INVOLVEMENT IN HMSN, VARIANT TYR-331, AND CHARACTERIZATION OF VARIANT
RP   TYR-331.
RX   PubMed=23454272; DOI=10.1016/j.ejmg.2013.02.002;
RA   Auer-Grumbach M., Bode H., Pieber T.R., Schabhuettl M., Fischer D.,
RA   Seidl R., Graf E., Wieland T., Schuh R., Vacariu G., Grill F.,
RA   Timmerman V., Strom T.M., Hornemann T.;
RT   "Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with
RT   a distinct syndromic phenotype.";
RL   Eur. J. Med. Genet. 56:266-269(2013).
RN   [22]
RP   VARIANT HSAN1A PHE-331.
RX   PubMed=24247255; DOI=10.3892/mmr.2013.1808;
RA   Suh B.C., Hong Y.B., Nakhro K., Nam S.H., Chung K.W., Choi B.O.;
RT   "Early-onset severe hereditary sensory and autonomic neuropathy type 1
RT   with S331F SPTLC1 mutation.";
RL   Mol. Med. Report. 9:481-486(2014).
CC   -!- FUNCTION: Serine palmitoyltransferase (SPT). The heterodimer
CC       formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The
CC       composition of the serine palmitoyltransferase (SPT) complex
CC       determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA
CC       complex shows a strong preference for C16-CoA substrate, while the
CC       SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as
CC       substrates, with a slight preference for C14-CoA. The SPTLC1-
CC       SPTLC2-SPTSSB complex shows a strong preference for C18-CoA
CC       substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an
CC       ability to use a broader range of acyl-CoAs, without apparent
CC       preference. {ECO:0000269|PubMed:19416851}.
CC   -!- CATALYTIC ACTIVITY: Palmitoyl-CoA + L-serine = CoA + 3-dehydro-D-
CC       sphinganine + CO(2). {ECO:0000269|PubMed:19416851}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.75 mM for serine {ECO:0000269|PubMed:20504773};
CC         Vmax=1350 pmol/min/mg enzyme {ECO:0000269|PubMed:20504773};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC   -!- SUBUNIT: Heterodimer with SPTLC2 or SPTLC3. Component of the
CC       serine palmitoyltransferase (SPT) complex, composed of SPTLC1,
CC       either SPTLC2 or SPTLC3, and either SPTSSA or SPTSSB. Interacts
CC       with SPTSSA and SPTSSB; the interaction is direct. Interacts with
CC       ORMDL3. {ECO:0000269|PubMed:19416851,
CC       ECO:0000269|PubMed:20182505}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250}; Single-pass membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15269-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15269-2; Sequence=VSP_043127, VSP_043128;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Not detected in small
CC       intestine. {ECO:0000269|PubMed:17023427}.
CC   -!- PTM: Phosphorylation at Tyr-164 inhibits activity and promotes
CC       cell survival. {ECO:0000269|PubMed:23629659}.
CC   -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 1A (HSAN1A)
CC       [MIM:162400]: A form of hereditary sensory and autonomic
CC       neuropathy, a genetically and clinically heterogeneous group of
CC       disorders characterized by degeneration of dorsal root and
CC       autonomic ganglion cells, and by prominent sensory abnormalities
CC       with a variable degree of motor and autonomic dysfunction. The
CC       neurological phenotype is often complicated by severe infections,
CC       osteomyelitis, and amputations. HSAN1A is an autosomal dominant
CC       axonal form with onset in the second or third decades. Initial
CC       symptoms are loss of pain, touch, heat, and cold sensation over
CC       the feet, followed by distal muscle wasting and weakness. Loss of
CC       pain sensation leads to chronic skin ulcers and distal
CC       amputations. {ECO:0000269|PubMed:11242114,
CC       ECO:0000269|PubMed:19132419, ECO:0000269|PubMed:19651702,
CC       ECO:0000269|PubMed:20504773, ECO:0000269|PubMed:21618344,
CC       ECO:0000269|PubMed:22302274, ECO:0000269|PubMed:24247255}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=SPTLC1 mutations at Ser-331 are responsible for
CC       severe hereditary motor and sensory neuropathy (HMSN) forms, whose
CC       core features are severe, diffuse muscle wasting and hypotonia,
CC       motor and sensory disturbances, foot ulcers, amputations and/or
CC       burns, joint hypermobility, cataracts and considerable growth
CC       retardation. {ECO:0000269|PubMed:23454272}.
CC   -!- SIMILARITY: Belongs to the class-II pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -!- CAUTION: Variant Ala-387 has been originally thought to cause
CC       HSAN1A (PubMed:15037712). Subsequently, it has been shown to be a
CC       rare, benign polymorphism found in homozygous state in a healthy
CC       individual (PubMed:19132419). {ECO:0000305|PubMed:15037712,
CC       ECO:0000305|PubMed:19132419}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y08685; CAA69941.1; -; mRNA.
DR   EMBL; AF286717; AAK29328.1; -; Genomic_DNA.
DR   EMBL; AF286703; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286704; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286705; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286706; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286707; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286708; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286709; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286710; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286711; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286712; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286713; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286714; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286715; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286716; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AK291546; BAF84235.1; -; mRNA.
DR   EMBL; AL391219; CAH70209.1; -; Genomic_DNA.
DR   EMBL; AL354751; CAH70209.1; JOINED; Genomic_DNA.
DR   EMBL; AL354751; CAH69923.1; -; Genomic_DNA.
DR   EMBL; AL354751; CAH69924.1; -; Genomic_DNA.
DR   EMBL; AL391219; CAH69924.1; JOINED; Genomic_DNA.
DR   EMBL; CH471089; EAW62804.1; -; Genomic_DNA.
DR   EMBL; BC007085; AAH07085.1; -; mRNA.
DR   CCDS; CCDS6692.1; -. [O15269-1]
DR   CCDS; CCDS6693.1; -. [O15269-2]
DR   RefSeq; NP_001268232.1; NM_001281303.1.
DR   RefSeq; NP_006406.1; NM_006415.3. [O15269-1]
DR   RefSeq; NP_847894.1; NM_178324.2. [O15269-2]
DR   UniGene; Hs.90458; -.
DR   ProteinModelPortal; O15269; -.
DR   SMR; O15269; -.
DR   BioGrid; 115809; 29.
DR   DIP; DIP-45626N; -.
DR   IntAct; O15269; 42.
DR   STRING; 9606.ENSP00000262554; -.
DR   BindingDB; O15269; -.
DR   ChEMBL; CHEMBL1250343; -.
DR   DrugBank; DB00133; L-Serine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; O15269; -.
DR   PhosphoSitePlus; O15269; -.
DR   SwissPalm; O15269; -.
DR   EPD; O15269; -.
DR   MaxQB; O15269; -.
DR   PaxDb; O15269; -.
DR   PeptideAtlas; O15269; -.
DR   PRIDE; O15269; -.
DR   Ensembl; ENST00000262554; ENSP00000262554; ENSG00000090054. [O15269-1]
DR   Ensembl; ENST00000337841; ENSP00000337635; ENSG00000090054. [O15269-2]
DR   GeneID; 10558; -.
DR   KEGG; hsa:10558; -.
DR   UCSC; uc004arl.3; human. [O15269-1]
DR   CTD; 10558; -.
DR   DisGeNET; 10558; -.
DR   GeneCards; SPTLC1; -.
DR   GeneReviews; SPTLC1; -.
DR   H-InvDB; HIX0034871; -.
DR   HGNC; HGNC:11277; SPTLC1.
DR   HPA; CAB018747; -.
DR   HPA; HPA010860; -.
DR   HPA; HPA063907; -.
DR   MalaCards; SPTLC1; -.
DR   MIM; 162400; phenotype.
DR   MIM; 605712; gene.
DR   neXtProt; NX_O15269; -.
DR   OpenTargets; ENSG00000090054; -.
DR   Orphanet; 36386; Hereditary sensory and autonomic neuropathy type 1.
DR   PharmGKB; PA36106; -.
DR   eggNOG; KOG1358; Eukaryota.
DR   eggNOG; COG0156; LUCA.
DR   GeneTree; ENSGT00550000074872; -.
DR   HOGENOM; HOG000216602; -.
DR   HOVERGEN; HBG003992; -.
DR   InParanoid; O15269; -.
DR   KO; K00654; -.
DR   OMA; QKYKLRL; -.
DR   OrthoDB; EOG091G0DOG; -.
DR   PhylomeDB; O15269; -.
DR   TreeFam; TF314877; -.
DR   BioCyc; MetaCyc:HS01673-MONOMER; -.
DR   BRENDA; 2.3.1.50; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SIGNOR; O15269; -.
DR   UniPathway; UPA00222; -.
DR   ChiTaRS; SPTLC1; human.
DR   GeneWiki; SPTLC1; -.
DR   GenomeRNAi; 10558; -.
DR   PRO; PR:O15269; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000090054; -.
DR   CleanEx; HS_SPTLC1; -.
DR   ExpressionAtlas; O15269; baseline and differential.
DR   Genevisible; O15269; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0017059; C:serine C-palmitoyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0035339; C:SPOTS complex; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0004758; F:serine C-palmitoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IDA:MGI.
DR   GO; GO:1904504; P:positive regulation of lipophagy; IDA:MGI.
DR   GO; GO:0046511; P:sphinganine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IDA:MGI.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:ProtInc.
DR   GO; GO:0006686; P:sphingomyelin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IEA:Ensembl.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Complete proteome;
KW   Disease mutation; Endoplasmic reticulum; Lipid metabolism; Membrane;
KW   Neurodegeneration; Neuropathy; Phosphoprotein; Polymorphism;
KW   Pyridoxal phosphate; Reference proteome; Sphingolipid metabolism;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    473       Serine palmitoyltransferase 1.
FT                                /FTId=PRO_0000163853.
FT   TOPO_DOM      1     15       Lumenal. {ECO:0000255}.
FT   TRANSMEM     16     36       Helical. {ECO:0000255}.
FT   TOPO_DOM     37    473       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES     164    164       Phosphotyrosine; by ABL.
FT                                {ECO:0000269|PubMed:23629659}.
FT   VAR_SEQ     143    143       D -> E (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043127.
FT   VAR_SEQ     144    473       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043128.
FT   VARIANT     133    133       C -> W (in HSAN1A; inactive in the
FT                                heterodimeric SPT complex; largely
FT                                reduced activity with serine as
FT                                substrate, but nearly no effect on serine
FT                                affinity in the heterotrimeric SPT
FT                                complex; in contrast to wild-type is able
FT                                to use alanine as substrate leading to
FT                                the formation of 1-deoxysphinganine (1-
FT                                deoxySa); does not interfere with SPT
FT                                complex formation; dbSNP:rs119482082).
FT                                {ECO:0000269|PubMed:11242114,
FT                                ECO:0000269|PubMed:19132419,
FT                                ECO:0000269|PubMed:20504773,
FT                                ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_011392.
FT   VARIANT     133    133       C -> Y (in HSAN1A; reduced activity; does
FT                                not interfere with SPT complex formation;
FT                                dbSNP:rs119482081).
FT                                {ECO:0000269|PubMed:11242114,
FT                                ECO:0000269|PubMed:19132419}.
FT                                /FTId=VAR_011393.
FT   VARIANT     144    144       V -> D (in HSAN1A; reduced activity; does
FT                                not interfere with SPT complex formation;
FT                                dbSNP:rs119482083).
FT                                {ECO:0000269|PubMed:11242114,
FT                                ECO:0000269|PubMed:19132419}.
FT                                /FTId=VAR_011394.
FT   VARIANT     151    151       R -> L (in dbSNP:rs45461899).
FT                                {ECO:0000269|PubMed:17060578}.
FT                                /FTId=VAR_037889.
FT   VARIANT     239    239       R -> W (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs542876370).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036610.
FT   VARIANT     310    310       A -> G (found in a patient with HSAN1A;
FT                                uncertain pathological significance;
FT                                dbSNP:rs768841574).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068476.
FT   VARIANT     331    331       S -> F (in HSAN1A; severe form with early
FT                                onset; reduced activity;
FT                                dbSNP:rs267607087).
FT                                {ECO:0000269|PubMed:19651702,
FT                                ECO:0000269|PubMed:21618344,
FT                                ECO:0000269|PubMed:24247255}.
FT                                /FTId=VAR_066245.
FT   VARIANT     331    331       S -> Y (probable disease-associated
FT                                mutation found in severe HMSN; reduced
FT                                activity). {ECO:0000269|PubMed:23454272}.
FT                                /FTId=VAR_073294.
FT   VARIANT     352    352       A -> V (in HSAN1A; reduced activity;
FT                                dbSNP:rs267607088).
FT                                {ECO:0000269|PubMed:19651702,
FT                                ECO:0000269|PubMed:21618344}.
FT                                /FTId=VAR_066246.
FT   VARIANT     387    387       G -> A (rare polymorphism; does not
FT                                affect activity; does not interfere with
FT                                SPT complex formation;
FT                                dbSNP:rs119482084).
FT                                {ECO:0000269|PubMed:15037712,
FT                                ECO:0000269|PubMed:19132419}.
FT                                /FTId=VAR_037890.
FT   MUTAGEN     164    164       Y->F: Increased serine
FT                                palmitoyltransferase activity and
FT                                sphingolipid content.
FT                                {ECO:0000269|PubMed:23629659}.
SQ   SEQUENCE   473 AA;  52744 MW;  BA9E056A869D2EA2 CRC64;
     MATATEQWVL VEMVQALYEA PAYHLILEGI LILWIIRLLF SKTYKLQERS DLTVKEKEEL
     IEEWQPEPLV PPVPKDHPAL NYNIVSGPPS HKTVVNGKEC INFASFNFLG LLDNPRVKAA
     ALASLKKYGV GTCGPRGFYG TFDVHLDLED RLAKFMKTEE AIIYSYGFAT IASAIPAYSK
     RGDIVFVDRA ACFAIQKGLQ ASRSDIKLFK HNDMADLERL LKEQEIEDQK NPRKARVTRR
     FIVVEGLYMN TGTICPLPEL VKLKYKYKAR IFLEESLSFG VLGEHGRGVT EHYGINIDDI
     DLISANMENA LASIGGFCCG RSFVIDHQRL SGQGYCFSAS LPPLLAAAAI EALNIMEENP
     GIFAVLKEKC GQIHKALQGI SGLKVVGESL SPAFHLQLEE STGSREQDVR LLQEIVDQCM
     NRSIALTQAR YLEKEEKCLP PPSIRVVVTV EQTEEELERA ASTIKEVAQA VLL
//
